-
The format of this article deviates somewhat from the usual style of footnotes sustaining the assertions of the article, because the purpose of this essay is to provide an introduction to alternative methods of dispute resolution in the healthcare field, which will be further examined in future articles.
-
-
Rate control vs rhythm control for atrial fibrillation continues to be debated with most of the evidence falling on the side of rate control in recent years, primarily because of adverse effects from anti-arrhythmics. A new drug may change that however.
-
The FDA has issued a public health advisory regarding the risk of progressive multifocal leukoencephalopathy (PML) associated with use of efalizumab (Raptiva®) for the treatment of psoriasis.
-
-
Get used to the word "pharmacogenetics" — the discipline of studying genetic variation and its effect on responses to drugs.
-
The FDA is considering new tightened restrictions on use of opioid drugs. Manufacturers of these drugs will be required to have a Risk Evaluation and Mitigation Strategy to ensure that "the benefits of the drugs continue to outweigh the risks."
-
-
-
I recall rounding on the oncology ward as a medical student. The prognosis in those days was bad for nearly every patient. Children with acute lymphoblastic leukemia were expected to live less than one year. Adults with acute myeloblastic leukemia, less than three months. What a difference in the past three decades.
With longer survival, however, there are more patients presenting with life-threatening emergencies related to their treatment and tumor.
